Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Hassan Mehrad-Majd"'
Autor:
Mohammad Esmaeeli, Mahin Ghorban Sabbagh, Sahar Ravanshad, Anoush Azarfar, Azade Oveisi Sani, Yalda Ravanshad, Hassan Mehrad-Majd
Publikováno v:
Journal of Renal Injury Prevention. 8:116-121
Context: To date, several studies have been done regarding the treatment of atypical hemolytic uremic syndrome (aHUS) which discussed eculizumab as a potential treatment for this syndrome. However, the safety and efficacy of eculizumab were not fully
Autor:
Sepideh Bagheri, Mohammad Esmaeeli, Anahita Alizadeh, Anoush Azarfar, Sahar Ravanshad, Aida Foroutan, Yalda Ravanshad, Hassan Mehrad-Majd
Publikováno v:
Journal of Renal Injury Prevention. 7:259-263
Introduction: Acute kidney injury (AKI) is known to be one of the major complications of critically ill children and accounts for a 30%-90% mortality of such patients. Early identification of such patients can significantly influence their mortality
Autor:
Anoush Azarfar, Mahmood Reza Khazaei, Sanaz Nastarani, Behnam Azimi, Hassan Mehrad-Majd, Shapour Badie Aval, Mojtaba Fazel, Yalda Ravanshad, Maryam Emadzadeh
Publikováno v:
Journal of Renal Injury Prevention. 7:307-313
To date, several studies have been done on efficacy and safety of drugs in children with refractory nephrotic syndrome (NS). Rituximab (RTX) might be a hopeful treatment for this syndrome. However, the long-term effects and cost-effectiveness of RTX